Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Lanfear

Showing results (1-10 of 175) with videos related to

Pageof 18
Sort By:
Heart Failure Reviews|October 14, 2008
Genetic variation in the natriuretic peptide system and heart failureDavid E Lanfear
Journal of Cardiac Failure|June 21, 2015
Waiting to Inhale … MilrinoneDavid E Lanfear
JACC. Heart Failure|July 5, 2023
Gut Microbiome in Cardiovascular Disease and Heart Failure: Seeing the Iceberg Below Its SurfacePetra Mamic, David E Lanfear
Current Heart Failure Reports|November 7, 2012
Ventricular assist devices: is destination therapy a viable alternative in the non-transplant candidate?Tara Hrobowski, David E Lanfear
Journal of the American College of Cardiology|October 6, 2022
Myosin-Related Dilated Cardiomyopathy: Another Elephant Emerges From DarknessDavid E Lanfear, Nosheen Reza
Journal of the American Heart Association|March 30, 2016
Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?Jasmine A Luzum, David E Lanfear
American Family Physician|November 10, 2007
Pharmacogenetics: using DNA to optimize drug therapyDavid E Lanfear, Howard L McLeod
Current Opinion in Molecular Therapeutics|June 4, 2010
Progress toward genetic tailoring of heart failure therapyJohn H Lillvis, David E Lanfear
Circulation. Heart Failure|July 13, 2018
Embracing the Long Road to Precision MedicineJulio A Chirinos, David E Lanfear
Current Heart Failure Reports|December 3, 2011
Pharmacogenetics in chronic heart failure: new developments and current challengesJasmine A Talameh, David E Lanfear
Pageof 18

Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
Heart Failure Reviews|October 14, 2008
Genetic variation in the natriuretic peptide system and heart failureDavid E Lanfear
Journal of Cardiac Failure|June 21, 2015
Waiting to Inhale … MilrinoneDavid E Lanfear
JACC. Heart Failure|July 5, 2023
Gut Microbiome in Cardiovascular Disease and Heart Failure: Seeing the Iceberg Below Its SurfacePetra Mamic, David E Lanfear
Current Heart Failure Reports|November 7, 2012
Ventricular assist devices: is destination therapy a viable alternative in the non-transplant candidate?Tara Hrobowski, David E Lanfear
Journal of the American College of Cardiology|October 6, 2022
Myosin-Related Dilated Cardiomyopathy: Another Elephant Emerges From DarknessDavid E Lanfear, Nosheen Reza
Journal of the American Heart Association|March 30, 2016
Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?Jasmine A Luzum, David E Lanfear
American Family Physician|November 10, 2007
Pharmacogenetics: using DNA to optimize drug therapyDavid E Lanfear, Howard L McLeod
Current Opinion in Molecular Therapeutics|June 4, 2010
Progress toward genetic tailoring of heart failure therapyJohn H Lillvis, David E Lanfear
Circulation. Heart Failure|July 13, 2018
Embracing the Long Road to Precision MedicineJulio A Chirinos, David E Lanfear
Current Heart Failure Reports|December 3, 2011
Pharmacogenetics in chronic heart failure: new developments and current challengesJasmine A Talameh, David E Lanfear
Pageof 18